Plasmid- and Inducer-Free Biosynthesis of Difucosyllactose through Rational Fusion Enzyme Engineering and Systematic Pathway Optimization
ACS Synthetic Biology · 2026
DOI: 10.1021/acssynbio.6c00229 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Synthetic Biology, 2026. Verfasst von Zhiqiang Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, Jiangnan University, Wuxi214122, China. Hauptthemen laut MEDLINE: Escherichia coli, Plasmids, Trisaccharides, Metabolic Engineering. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Key Technological Project of Jiangxi Province, National Basic Research Program of China (973 Program).
Abstract (Originalsprache)
Difucosyllactose (DFL), a fucosylated human milk oligosaccharide, exhibits significant application potential in the food and pharmaceutical industries. However, the microbial production of DFL faces challenges such as the accumulation of the intermediate 2′-fucosyllactose (2′-FL) and the high costs associated with the use of antibiotics and inducers. In this study, we constructed a plasmid- and inducer-free Escherichia coli MG1655 strain to enhance the biosynthesis of DFL while minimizing 2′-FL accumulation. Initially, the de novo DFL biosynthetic pathway was established by introducing different α-1,3-fucosyltransferases (α-1,3-FucT) into a 2′-FL-producing strain. Combinatorial metabolic engineering strategies were then employed to improve DFL accumulation. Subsequently, guided by the in silico multienzyme assembling by reshaping space (iMARS) framework, a fusion enzyme, FucTaY218K-L60-FutC, was rationally designed to effectively alleviate 2′-FL accumulation. Furthermore, modulation of the hydrophobic microenvironment in the substrate-binding pocket of FucTaY218K yielded the beneficial mutant FucTaY218K/W31R. Finally, modifications to the lactose operon significantly improved strain growth while concurrently enhancing DFL production. The best-performing strain achieved a DFL titer of 74 g/L in a 5-L bioreactor, corresponding to a productivity of 0.96 g/L/h, representing the highest productivity reported to date. This study establishes a robust and environmentally friendly platform for the industrial-scale production of DFL and provides a strategy for the microbial synthesis of other high-value human milk oligosaccharides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, Jiangnan University, Wuxi214122, China.
- Science Center for Future Foods, Jiangnan University, Wuxi214122, China.
ORCID-Profile: Yanfeng Liu, Xueqin Lv, Long Liu
Förderung
- Fundamental Research Funds for the Central Universities
- Key Technological Project of Jiangxi Province
- National Basic Research Program of China (973 Program)
- National Natural Science Foundation of China (NSFC)
- Jiangsu Basic Research Center for Synthetic Biology
Zitieren
APA
Liu, Z., Li, B., Deng, J., Liu, Y., Li, J., Du, G., Chen, J., Lv, X., Xu, X., & Liu, L. (2026). Plasmid- and Inducer-Free Biosynthesis of Difucosyllactose through Rational Fusion Enzyme Engineering and Systematic Pathway Optimization. ACS Synthetic Biology. https://doi.org/10.1021/acssynbio.6c00229
Vancouver
Liu Z, Li B, Deng J, Liu Y, Li J, Du G, et al. Plasmid- and Inducer-Free Biosynthesis of Difucosyllactose through Rational Fusion Enzyme Engineering and Systematic Pathway Optimization. ACS Synthetic Biology. 2026. doi:10.1021/acssynbio.6c00229
BibTeX
@article{Liu2026,
author = {Liu, Zhiqiang and Li, Binglin and Deng, Jieying and Liu, Yanfeng and Li, Jianghua and Du, Guocheng and Chen, Jian and Lv, Xueqin and Xu, Xianhao and Liu, Long},
title = {Plasmid- and Inducer-Free Biosynthesis of Difucosyllactose through Rational Fusion Enzyme Engineering and Systematic Pathway Optimization},
journal = {ACS Synthetic Biology},
year = {2026},
doi = {10.1021/acssynbio.6c00229}
}
EUVIMED